Acute Myeloid Leukemia (AML), a severe form of blood cancer, often involves activating mutations of FLT3 that lead to uncontrolled growth and survival of hematopoietic stem and progenitor cells (HSC/Ps). These mutations are associated with poor overall survival, and current treatments targeting mutant FLT3, such as Quizartinib and Crenolanib, frequently face resistance due to additional mutations and survival pathways.
A recent publication highlights a significant breakthrough in the treatment of AML. Researchers have identified two novel nicotinamide-based FLT3 inhibitors, HSN608 and HSN748, which demonstrate remarkable efficacy at subnanomolar concentrations. These compounds are effective against drug-resistant secondary mutations and show potent antileukemic activity in various AML contexts, including drug-resistant AML, relapsed/refractory AML, and AML with combined epigenetic mutations of TET2 and FLT3ITD.
Notably, HSN748 has outperformed the FDA-approved FLT3 inhibitor Gilteritinib in terms of inhibitory activity against FLT3ITD in vivo. These findings suggest that HSN608 and HSN748 could represent a significant advancement in AML therapy, providing new hope for patients struggling with this aggressive disease.
This development underscores the potential of these novel inhibitors to revolutionize the treatment landscape for AML, addressing a critical need for more effective targeted therapies.
Read the full article in The Journal of Clinical Investigation here.